Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pipemidic Acid→

Pipemidic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51940-44-4
Molecular formula
C14H17N5O3
Molecular weight
303.32 g/mol
Drug class
Quinolone antibacterialbacterial DNA gyrase and topoisomerase inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication and transcription. It is concentrated in urine and bile and has antibacterial activity primarily against Gram-negative organisms, with activity against some Gram-positive bacteria.
Indications / reported uses
  • Historically used for urinary, biliary and gastrointestinal infections caused by susceptible bacteria. It is an older quinolone with jurisdiction-specific availability and should not be treated as a preferred contemporary empiric antibiotic.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68010876 · https://meshb.nlm.nih.gov/record/ui?ui=D010876 · https://pubchem.ncbi.nlm.nih.gov/compound/Pipemidic-Acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pipemidic Acid Environmental Risk Assessment (ERA) (the Pipemidic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.